651744-48-8

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]-
• Synonyms: 4-Chloro-1-(triisopropylsilyl)-7-azaindole;4-Chloro-1-(triisopropyls...;4-chloro-1-[tris(1-Methylethyl)silyl]-1H-Pyrrolo[2,3-b]pyridine;(4-Chloropyrrolo[2,3-b]pyridin-1-yl)-triisopropyl-silane;4-chloro-1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine;4-Chloro-1-(triisopropylsilyl);1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]-
• CAS NO: 651744-48-8
• Molecular Formula: C₁₆H₂₅ClN₂Si
• Molecular Weight: 308.93
• Mol File: 651744-48-8.mol

Chemical Properties

• Boiling Point: 320.543ºC at 760 mmHg
• Flash Point: 147.659ºC
• Appearance: /
• Density: 1.058g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.34±0.30(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]-(651744-48-8)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]-(651744-48-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 651744-48-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]is used as a key intermediate in organic synthesis for the creation of various biologically active compounds. Its unique structure allows for the development of new chemical entities with potential applications across different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]is utilized as a building block for the synthesis of new drugs. Its structural features make it a promising candidate for the development of innovative therapeutic agents.
Used in Agrochemical Development:
1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]is also studied for its potential in agrochemicals, where it may contribute to the design of new pesticides or other agricultural chemicals, enhancing crop protection and yield.
Used as a Protecting Group in Organic Chemistry:
The tris(1-methylethyl)silyl group in 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[tris(1-methylethyl)silyl]serves as a protecting agent for reactive functional groups during chemical reactions. This makes the compound a valuable reagent in organic chemistry, facilitating cleaner syntheses and preventing unwanted side reactions.

InChI:InChI=1/C16H25ClN2Si/c1-11(2)20(12(3)4,13(5)6)19-10-8-14-15(17)7-9-18-16(14)19/h7-13H,1-6H3

Upstream product

• 13154-24-0 triisopropylsilyl chloride 
• 55052-28-3 4-chloro-7-azaindole 
• 80522-42-5 triisopropylsilyl trifluoromethanesulfonate 

Downstream Products

• 685513-97-7 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 
• 685514-01-6 1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridin-5-ol 
• 942261-81-6 (4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine-5-yl)phenylmethanol 
• 924655-39-0 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde 
• 958230-19-8 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde 
• 1310731-53-3 C₂₃H₂₇N₃O₄S 
• 1310731-55-5 C₂₁H₂₃N₃O₃S 
• 1310731-56-6 C₂₅H₂₉N₃O₄S 
• 1310731-57-7 C₂₅H₃₁N₃O₄S 
• 1310731-58-8 C₂₃H₂₇N₃O₂S 
• 1310728-84-7 1-cyclohexyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h][1,6]naphthyridine 
• 1310731-54-4 C₂₁H₂₅N₃O₃S 
• 1310704-15-4 ethyl 4-chloro-1-(triisopropylsilyl)-7-azaindole-5-carboxylate 
• 1420885-83-1 N-methyl-2-[2-(6-morpholin-4-ylpyridin-3-yl)-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzamide 

Relevant articles and documents

Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3

Janus kinases (JAKs) have been known to play crucial roles in modulating a number of inflammatory and immune mediators. Here, we describe a series of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting JAK3 for use in treating immune diseases such as organ transplantation. In the chemical modification of compound 6, the introduction of a carbamoyl group to the C5-position and substitution of a cyclohexylamino group at the C4-position of the 1H-pyrrolo[2,3-b]pyridine ring led to a large increase in JAK3 inhibitory activity. Compound 14c was identified as a potent, moderately selective JAK3 inhibitor, and the immunomodulating effect of 14c on interleukin-2-stimulated T cell proliferation was shown. Docking calculations and WaterMap analysis of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives were conducted to confirm the substituent effects on JAK3 inhibitory activity.

JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF

A 7-azaindole derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I), and uses of the compound in preparing a medicament for preventing or treating Janus kinase (JAK) family-related diseases, specifically, uses in preventing or treating inflammatory diseases related to protein tyrosine kinase.

Compound with pyrrolopyridine structure, preparation method and medical application

The invention discloses a compound with a pyrrolopyridine structure, a preparation method and medical application. The compound with the pyrrolopyridine structure has obvious inhibitory activity on JAK family proteins, and is an effective JAK inhibitor, so that the compound has a prospect of being developed into drugs for inhibiting JAK and further treating diseases.

Compound of dipyrrolopyridine structure Preparation method and medical application

The invention discloses a compound with a dipyrrolo-pyridine structure as well as a preparation method and medical application thereof. The compound provided by the invention has obvious inhibitory activity on JAK family proteins, is an effective JAK inhibitor, and has the prospect of being developed into drugs for inhibiting JAK and further treating diseases.

DERIVATIVES OF AN FGFR INHIBITOR

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

CHEMICAL COMPOUNDS

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME

The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

Substituted heteroaryl compound and composition and application thereof

The invention provides a substituted heteroaryl compound and a pharmaceutical composition and application thereof. The compound is a compound as shown in formula (I) or the stereisomer, tautomer, nitric oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in formula (I). The pharmaceutical composition containing the compound can regulate the activity ofprotein kinase and especially the activity of Aurora kinase and JAK kinase and is used for preventing, treating and relieving diseases or disorder mediated by protein kinase and especially JAK kinase.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

TAM KINASE INHIBITORS

Described herein are compounds, methods of making such compounds, compositions (e.g., pharmaceutical compositions/medicaments) that include such compounds, and methods of using such compounds to treat diseases, such as cancer.